NCT07086443招募中4 期
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating Placental Derived Allografts and Standard of Care in the Treatment of Nonhealing Diabetic Foot Ulcers Using Matched Controls
Sequence LifeScience, Inc.2 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2025年7月11日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 350
- 试验地点
- 2
- 主要终点
- Between-arm difference in subjects achieving complete closure
研究概览
简要总结
The goal of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.
详细描述
This study is a prospective modified platform multicenter randomized controlled clinical trial. The goal of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The potential subject must be at least 18 years of age or older.
- •The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
- •At enrollment, the potential subject must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 15.0 cm2 measured post debridement with the imaging device length times width.
- •The potential subject must have a target ulcer that has been present for a minimum of 4 weeks of standard of care, prior to the initial screening visit.
- •The potential subject must have a target ulcer located on the foot with at least 50% of the ulcer below the malleolus.
- •The potential subject must have a target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
- •The potential subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- •ABI between 0.7 and ≤ 1.3;
- •TCOM ≥ 40 mmHg;
- •PVR: biphasic.
- •If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and
排除标准
- •will be designated as the target ulcer.
- •The potential subject must have a target ulcer located on the 50% below the malleolus and not on the dorsal toes.
- •The ulcer must be offloaded for at least 14 days prior to enrollment.
- •The potential subject must consent to using the prescribed offloading method for the duration of the study.
- •The potential subject must agree to attend the weekly study visits required by the protocol.
- •The potential subject must be willing and able to participate in the informed consent process.
- •Exclusion Criteria:
- •The potential subject is known to have a life expectancy of < 6 months.
- •The potential subject's target ulcer is not secondary to diabetes.
- •The target ulcer is infected or there is cellulitis in the surrounding skin.
- •The target ulcer exposes tendon or bone.
- •There is evidence of osteomyelitis complicating the target ulcer.
- •The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
- •The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
- •The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
- •The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
- •The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
- •The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.
- •The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
- •The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
- •The potential subject has end stage renal disease requiring dialysis.
- •The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
- •The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
- •The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
- •The potential subject has a malnutrition.
- •The potential subject has a known allergy or sensitivity to PBS, IPA, processing solutions, reagents, or latex.
研究组 & 干预措施
Activate™ Matrix +SOC
Experimental
Three layers: amnion, intermediate layer, and chorion
干预措施: Activate™ Matrix (Other)
AmnioDefend™ FT Matrix +SOC
Experimental
Three layers: amnion, intermediate layer, and chorion
干预措施: AmnioDefend™ FT Matrix (Other)
Palisade™ DM Matrix +SOC
Experimental
Two layers: amnion and chorion
干预措施: Palisade™ DM Matrix (Other)
Sentry™ SL Matrix +SOC
Experimental
One layer: amnion
干预措施: Sentry™ SL Matrix (Other)
Enclose™ TL Matrix +SOC
Experimental
Three layers: amnion, chorion, amnion
干预措施: Enclose™ TL Matrix (Other)
Shelter™ DM Matrix +SOC
Experimental
Two layers: amnion and chorion
干预措施: Shelter™ DM Matrix + SOC (Other)
结局指标
主要结局
Between-arm difference in subjects achieving complete closure
时间窗: 1-12 Weeks
To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.
次要结局
- Time to closure(1-12 weeks)
- Percentage area reduction rate(1-12 weeks)
- Adverse Events(1-12 Weeks)
- Determine Quality of Life(1-12 weeks)
- Determine quality of life(1-12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
4 期
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg UlcersVenous Leg Ulcer (VLU)Venous Leg UlcersVenous LegNonhealing Venous Leg UlcerNCT06693570Kerecis Ltd.150
撤回
4 期
Comparison of Chitosan and Carboxymethylcellulose Silver Dressings on Burn Wounds in Pediatric and Adult SubjectsBandagesNCT02353507Medline Industries
已完成
不适用
Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - StudyCOPD Patients With Homogeneous EmphysemaEndoscopic Lung Volume Reduction With Endobronchial ValveNCT02025205Pulmonx International Sàrl93
进行中（未招募）
不适用
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous LevelsCervical Disc DiseaseNCT04564885Spineart USA300
Unknown
不适用
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc DiseaseCervical Disc DiseaseNCT04520776Spineart USA284